NCT06682247View on ClinicalTrials.gov

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

June 15, 2025

Study Completion Date

December 31, 2025

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

All Listed Sponsors
lead

Feng Wang

OTHER

NCT06682247 - A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer | Biotech Hunter | Biotech Hunter